MDS
Virtual Congress
2021SEPTEMBER 17-22, 2021 www.mdscongress.org
MDS-1120-177
GUIDED POSTER TOURS
LISTING
MDS Virtual Congress 2021 Guided Poster Tour Abstract Reference ____________________________________________________
Guided Poster Tour 1: Ataxia, chorea, tics, RLS
20
Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile-X Associated Tremor/Ataxia Syndrome
36
Extracerebellar Signs and Symptoms in 117 Korean Patients with Early-Stage
Spinocerebellar Ataxia 34
Evolution of disability in spinocerebellar ataxias type 1, 2, 3, and 6
57
Normal chorein protein signal on Western blot despite VPS13A mutations in VPS13A disease 229
Characterising the incidence of comorbidities, hospitalisations, and death in patients
diagnosed with Huntington’s disease: A cohort study of linked Swedish National Registries (2002-2019)
230
Evolving inclusion criteria in early manifest Huntington’s disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial
231
Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
244
Comparison of correlations of structural magnetic resonance imaging measures with smartphone-based active tests and clinical tests in Huntington’s disease
1201
Prevalence of Restless Legs Syndrome in the South African population
1209
Restless leg syndrome and atherosclerosis:
prospective study in the Canadian Longitudinal Study on Aging
1326
Positive effect of Medical Cannabis in adults with Tourette syndrome
1328
The Association Between Tic Disorders and Atopy
Guided Poster Tour 2: Atypical Parkinsonism: MSA, PSP, CBD
559
Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
562
Deep gray matter atrophy in MSA subtypes 568
Mapping regional alpha-synuclein seeding capacity in Multiple System Atrophy
574
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy compared to Parkinson’s Disease
575
Progression of nigro-striatal denervation in cerebellar Multiple System Atrophy: a prospective study
586
Automated Midbrain-Pons Ratio using Artificial Intelligence Differentiates PSP from other Atypical Parkinsonian Disorders
589
Neuroimaging associations to gait impairments in progressive supranuclear palsy
593
Plasma microRNA expression profiling in patients with progressive supranuclear palsy. A five-microRNA panel in plasma was identified as a potential biomarker for progressive
supranuclear palsy 594
Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders
Guided Poster Tour 3: Clinical Trials – Parkinson’s Disease
73
Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8
370
A Milestone-based approach to monitoring disease progression in Parkinson's disease 379
Home Health Management of Parkinson’s Disease Deep Brain Stimulation: A Randomized Clinical Trial
384
Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in
Parkinson’s Disease 396
Effects of Opicapone on Sleep in Patients with Parkinson’s Disease and Motor Fluctuations 399
FIRST-IN-MAN CLINICAL TRIAL OF
INTRAPUTAMENAL CDNF IN PARKINSON’S
DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS 404
Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and
Immunogenicity of ABBV-0805, an Anti-Alpha- Synuclein Monoclonal Antibody in Healthy Subjects
416
Efficacy of a 6-week brisk walking program in improving non-motor symptoms in people with Parkinson disease - a randomized controlled trial
429
A Phase 2 Randomized Controlled Trial
Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.
430
Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson's Disease
432
Feasibility of dance therapy through synchrony videoconference in Parkinson’s disease and elderly people.
450
Impact of specialized light therapy in
Parkinson’s disease on MDS-UPDRS parts 1-3 subscales
Guided Poster Tour 4: Clinical Trials - Other Movement Disorders (non-PD)
64
Cerebellar tDCS for multiple system atrophy cerebellar: Double blinded, randomized, sham- control, cross-over study
65
The Effect of Electromyography Biofeedback on The Frequency of Clenching on Patients with Bruxism
68
Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome
69
Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
70
Real-World Evidence Supports use of
Transcutaneous Afferent Patterned Stimulation for Tremor Control in Veteran’s Affairs Essential Tremor Patients
74
Effects of Gandouling Tablets on the Muscle tone and stiffness of patients with Wilson’s disease: a randomized, double-blind, placebo- controlled study
93
A real-life study of Medical Cannabis effect on adults with dystonia
99
Tele-yoga for individuals with cervical dystonia:
A pilot study 100
A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia 103
Improvement of non-motor symptoms and quality of life after DBS stimulation for refractory dystonia: a one-year follow-up 109
Approaching the lateral pterygoid muscle in botulinum toxin injections. How to avoid the maxillary artery
107
Pain in cervical dystonia: A meta-analysis of outcomes following treatment with
abobotulinumtoxinA in randomized, controlled clinical studies
Guided Poster Tour 5: Cognitive and psychiatric disturbances in Parkinson’s Disease 167
Early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia: A Population- based Study (2010-2015).
215
Differential methylation signatures in Lewy body dementia
441
Single-Trajectory Multiple-Target Deep Brain Stimulation to treat Mobility and Cognition in Parkinson’s Disease: a Double-Blind,
Randomized, Cross-Over Pilot Study 649
Prevalence of Suicidal Ideation and Associated Clinical Features in Lewy Body Dementia 675
The dual cognitive syndrome in Parkinson’s disease: a resting-state functional connectivity study
676
Cognitive reserve in non-demented patients with Parkinson’s disease might protect against amyloid burden effect on cognition
670
Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with
Parkinson’s disease 680
Initial longitudinal analyses of objectively assessed cognitive functional abilities in a cohort with Parkinson’s disease
685
Cognitive-driven ADL impairment as a predictor for PDD
702
Facial emotion recognition and social behavioral problems in de novo parkinson’s disease
patients 709
Statistical methods for dealing with missing data in longitudinal studies with application to Parkinson’s disease cognition research
1052
Apathy: an underestimated feature in premotor period of GBA and LRRK2 non-manifesting mutation carriers.
Guided Poster Tour 6: Dystonia, Tremor
126
Tremor in Writer’s Cramp Patients 132
Non-Motor Symptoms in Cervical Dystonia Patients
139
A study of microstructural changes and functional connectivity in cranial, cervical, and cranio-cervical segmental dystonia by
multimodal MRI
1063
Clinical profile and treatment outcomes of inherited hypermanganesemia among 27 Indian children: A retrospective multi-centric study 1340
MR guided high-intensity ultrasound thalamotomy in essential tremor and
Parkinson´s disease: is there an ideal candidate?
1343
Wearable Sensor-Driven Responsive Deep Brain Stimulation for Essential Tremor
1346
Essential tremor versus essential tremor-plus:
Response to ventralis intermedius nucleus deep brain stimulation
1347
Bilateral focused ultrasound thalamotomy for essential tremor (BEST-FUS trial): safety and efficacy proof of principle
1366
Neuronal intranuclear inclusion disease tremor- dominant subtype: a mimicker of essential tremor
Guided Poster Tour 7: Epidemiology & Rating Scales
87
Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results
170
Racial and ethnic differences in patients with Parkinson’s Disease across Parkinson’s Disease Centers of Excellence
171
Clinical and Economic Outcomes Associated with Dysphagia in Hospitalized Patients with Parkinson's Disease
172
Is the association between cigarette smoking and Parkinson disease causal? A Mendelian Randomization study.
175
Clinical epidemiology of movement disorders in Douala General Hospital, Cameroon: A two years retrospective study
184
Mortality of people with Parkinson’s disease in a large population-based cohort study. Time trends and relationship to disease progression.
190
Emerging parkinsonism in the PREDICT-PD cohort after 6-years of follow-up
191
Prevalence of advanced Parkinson’s disease in Thai patients with Parkinson’s disease using The Consensus on the Definition of Advance
Parkinson’s disease (CEPA Study): A single- center study
420
Towards an automated rating of the MDS- UPDRS motor scores.
605
Coffee, smoking and aspirin are associated with age at onset and clinical severity in idiopathic Parkinson’s disease
684
Analysis of effectiveness of Montreal Cognitive Assessment as cognitive evaluation method in low education level patients with Parkinson's disease in the Brazilian Amazon.
1186
The Gastrointestinal Dysfunction Scale – Parkinson’s Disease (GIDS-PD): a new tool to assess gastrointestinal dysfunction in Parkinson’s Disease
1188
Does MDS-UPDRS provide greater sensitivity to mild disease than UPDRS for assessing motor severity in early Parkinson's disease?
Guided Poster Tour 8: Neurophysiology of Movement Disorders
296
Unravelling Voice Tremor In Movement Disorders: A Machine Learning Study 297
Electrophysiological testing aids the diagnosis of tremor versus myoclonus in clinically
challenging patients 299
Surround inhibition (SI) in the human motor system during real life motor tasks.
300
Promising Biomarkers for Task Specific Dystonia 302
Closing the Loop on Essential Tremor Using Thalamic and Cortical Control Signals 303
Can event-related oscillations aid in differentiating Parkinson's disease and dementia with Lewy bodies?
304
Spinal Excitability and Plasticity in Hereditary Spastic Paraparesis: A Neurophysiological Study 895
Pallidal deep brain stimulation entrains finely tuned gamma oscillations in motor cortex 910
Preoperative EEG-based Machine Learning predicts cognitive deterioration after STN DBS in Parkinson's Disease patients
920
Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
921
Chronic sensing of the subthalamic nucleus in Parkinson’s disease patients: preliminary observations
924
Abnormalities of vestibular-evoked myogenic potentials are associated with REM sleep without atonia in early Parkinson’s disease and idiopathic REM sleep behavior disorder
Guided Poster Tour 9: Parkinson's Disease – Genetics
711
The study of genetic factors in motor levodopa- induced complications development in Russian patients with Parkinson's disease
715
Digenic R1441G-LRRK2 and Parkin mutations in Parkinson's Disease: first clinicopathological case report.
728
Novel PLA2G6 Mutation Presenting as Early- Onset Parkinson’s Disease
730
α-Synuclein in sympathetic nerve fibers distinguishes PRKN from LRRK2 and other genetic forms of Parkinson’s Disease 731
Building a Global Parkinson's Genetics Program (GP2): Clinical Cohorts Integration Working Group
744
Glucocerebrosidase activity does not predict Parkinson's Disease risk or severity
751
The Global Parkinson's Genetics Program (GP2) Underrepresented Populations Working Group 752
Lack of diversity in Parkinson's disease genetic research: current landscape and future directions
753
Stratified genome-wide association study revealed novel interactions for the top hit Parkinson’s disease loci.
765
Analysis of the HLA locus in isolated REM sleep behavior disorder and Lewy body dementia 766
Lysosomal storage disorder genes variants in Parkinson’s disease: a large cohort study in Chinese mainland population
Guided Poster Tour 10: Parkinson's Disease - Molecular Mechanisms
772
MicroRNAs as a potential biomarker of Parkinson’s disease
775
Parkinson’s disease-linked LDL Receptor Related Protein 10 (LRP10) is implicated in regulation of the secretory and autophagy-lysosome
pathways 779
Fatty acids and Glucocerebrosidase activity as potential biomarkers of stearyl-CoA desaturase inhibition; an observational study of inter and intraday variation in healthy volunteers and patients with Parkinson’s disease
778
Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson’s disease
785
Next-generation sequencing of plasma- associated extracellular vesicle miRNAs as potential biomarkers for Parkinson’s disease and its prodromal stage
786
The gut microbiome in Parkinson’s disease:
longitudinal insights into disease progression and the use of device-assisted therapies.
787
Gut microbiota and nutritional profiles of Parkinson’s disease patients.
788
Double labeling alpha-synuclein in labial minor salivary glands in Parkinson’s disease and idiopathic RBD patients
793
Neurofilament light chain serum levels in E46K- SNCA mutation carriers
799
α-synuclein and deficits of membrane trafficking in Parkinson's Disease 803
Whole-transcriptome analysis of monocyte- derived macrophages from patients with Parkinson’s disease associated with mutations in the GBA gene
Guided Poster Tour 11: Parkinson's disease – Neuroimaging
808
Neurogenetic Traits Outline Vulnerability to Cortical Disruption in Parkinson’s Disease 833
In-vivo cholinergic basal forebrain degeneration and cognition in Parkinson’s disease: imaging results from the COPPADIS study
834
Striatal dopaminergic loss in early clinically unilateral Parkinson’s disease: a systematic review
843
Parkinson Disease with, but not without, Cognitive Decline Reveals Advanced Brain Aging 850
Characteristics of the amyloid beta networks in Parkinson’s disease patients: a PPMI study
867
Cognition-related functional topographies in Parkinson’s disease: Localized loss of the ventral default mode network
873
Regional brain iron and gene expression variation in Parkinson’s disease
885
Longitudinal Study of Grey Matter Nuclei in Early Parkinson’s Disease using Diffusion Kurtosis Imaging
891
Locus coeruleus degeneration associated with less levodopa responsiveness in Parkinson’s Disease
892
Increased free-water in the substantia nigra in idiopathic REM sleep behaviour disorder
Guided Poster Tour 12: Parkinson's Disease - Non-motor Symptoms
435
Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial 930
Locus coeruleus volume is reduced in Parkinson disease-related orthostatic hypotension.
932
Autonomic Symptoms as Predictors of Quality of Life in Parkinson’s Disease: A 5-year follow up study
942
Relationship between low back pain-related disability and motor performance in people with Parkinson disease
954
Disentangling prodromal from non-prodromal symptoms of Parkinson's disease
971
Physical activity (PA), patient reported outcomes and quality of life in Parkinson’s disease( PD)
988
Comparison of gastrointestinal transit times in typical and erratic levodopa-responders in patients with Parkinson’s disease.
994
The Impact of Back and Neck Pain in Parkinson’s Disease: The PD-PAIN Study
1004
Serial olfactory testing for the diagnosis of prodromal Parkinson disease in the Parkinson Associated Risk Syndrome (PARS) study 1012
Visual Impairment along Parkinsonism
Development and the Association to Non-vision dependent Cognitive Decline: A
Prospective Nation-wide CLSA study
1015
Improvement of excessive daytime sleepiness with low frequency repetitive transcranial magnetic stimulation in Parkinson’s disease: a preliminary sham-controlled study
1048
Evaluation of bedside tests of attention in delirium superimposed on Parkinson’s disease and dementia
Guided Poster Tour 13: Surgical Therapy
1218
Safety and effectiveness of unilateral MRgFUS thalamotomy in elderly patients with essential and parkinsonian tremor
1222
Synergistic effects of short pulse and directional deep brain stimulation of the thalamic ventral intermediate area for essential tremor 1223
Deep brain stimulation (DBS) of the ventral- intermediate thalamic nucleus (VIM) compared to the posterior subthalamic area (PSA) for upper limb action tremor: A single-center, randomized, double-blind, crossover trial (Oslo Tremorstim study)
1228
Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation 1229
Long-term clinical outcome of deep brain stimulation in pantothenate kinase-associated neurodegeneration: a retrospective
observational study
1233
Safety and efficacy of unilateral
subthalamotomy by magnetic resonance guided focused ultrasound (MRgFUS) in asymmetrical Parkinson’s disease (PD).
1238
Reasons for refusing deep brain stimulation in patients with Parkinson's disease: a
retrospective 10-year study 1242
Real-World Outcomes Using a Novel Directional Lead from a Multicenter DBS Registry for Parkinson's Disease
1243
Long-Term Motor Function and Quality of Life Outcomes from a Prospective, International DBS Registry
1258
Real-World Deep Brain Stimulation Outcomes Using Directional DBS Systems with Multiple Independent Current Control
1264
Combined effects of GBA mutations and STN- DBS negatively impact cognition in Parkinson’s disease
1269
Predicting MDS-UPDRS Ratings for Deep Brain Stimulation Patients Using Wearable Sensor Data
Guided Poster Tour 14: Technology
1273
Automatic Estimation of MDS-UPDRS Gait Scores from Videos with Multi-Rater Disagreements
1275
Visualization Tool for DBS Programming with a Multiple Source, Constant Current System Reduces Initial Programming Time
1288
Co-designing a meaningful, humane and personalized eHealth platform (eCARE-PD) for people living with Parkinson's Disease
1291
A Machine Learning Approach to VTA Prediction in DBS
1300
Using Machine Learning to Predict the Best Outcomes with Electrical Muscle Stimulation for Tremors in Parkinson’s Disease
1303
Multimodal Conversational AI for Remote Patient Monitoring and Analysis of Parkinson’s Disease
1304
Building a Data Base for Automatic Speech Recognition in Parkinson's disease (PD) 1310
A Computer-Vision Based Method for Quantifying Parkinsonian Gait
1315
Quantitative gait analysis using a pose-
estimation algorithm with a single 2D-video of PD patients
1318
Effect of dopaminergic treatment on digital sensor features in Phase II PASADENA Part 1 in early Parkinson’s disease
1320
Evaluating the use of digital biomarkers to test treatment effects on cognition and motor in patients with Lewy Body Dementia
Guided Poster Tour 15: COVID-19 and Movement Disorders
95
Botulinum Toxin Injections For Movement Disorders During the COVID-19 Pandemic: A Single-Center Experience
185
The COVID-19 Pandemic Impact on Advanced Parkinson’s Disease in the US
186
COVID-19 outcomes in hospitalized patients with pre-existing neurodegenerative diseases in Chicagoland area
332
Parkinson’s disease and Post-COVID-19 syndrome
534
Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory
lockdown and its management with the help of Telemedicine in a North Indian cohort
626
Post-Covid-19 Parkinson’s disease: a Brazilian case series.
638
Physical activity and subjective perception of PD symptoms during COVID-19 lockdown: a clinical audit
654
Parkinson’s disease patients may be at higher risk of Covid-19 mortality
1155
People living with Parkinson’s disease during the COVID-19 Pandemic: A cross-sectional survey of the Canadian experience
1165
The impact of lockdown due to the COVID-19 pandemic on Asian cervical dystonia patients treated with Botulinum toxin injections 1331
Explosive onset of tic-like movements during the COVID pandemic among patients with no previous diagnosis of tic disorders
Guided Poster Tour 16: Late-Breaking Abstracts
LBA 1
Triheptanoin is associated with clinical stability and decreased caudate atrophy in Huntington disease
LBA 2
Efficacy of Omaveloxolone in Patients with Friedreich’s Ataxia: Delayed-Start Study LBA 3
Omics profile of iPSC-derived astrocytes from Progressive Supranuclear Palsy (PSP) patients LBA 4
MDS Survey of Genetic Testing and Counseling Practices for Parkinson Disease
LBA 5
Delayed-start analysis of PASADENA: A randomised Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease; Part 2 Week 104 results
LBA 6
Reduction of total LRRK2 in human CSF with LRRK2 inhibitor treatment demonstrates CNS target engagement and utility of total LRRK2 as a pharmacodynamic biomarker
LBA 7
CRISPR engineering of a dystonia-specific allelic series of THAP1 mutations reveals
transcriptional profiles associated with myelination and neurodevelopment LBA 8
Multicenter, randomized, double-blind, placebo controlled clinical trial with riluzole in
spinocerebellar ataxia type 2 LBA 9
A data-driven model of brain atrophy
progression in Progressive Supranuclear Palsy.
LBA 10
SAGE-324/BIIB124, an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM), in patients with essential tremor: results from the phase 2 KINETIC trial LBA 11
Deterministic tractography-based versus indirect-targeting magnetic resonance-guided focussed ultrasound treatment of medication- refractory essential tremor: 3-year results of a prospective cohort study